Clinical trials: Myeloproliferative Syndrome
Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
This trial will evaluate the safety and efficacy of a reduced intensity allogeneic HSCT from partially HLA-mismatched first-degree relatives utilizing PBSC as the stem cell source.
- Conditions
- Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia
- Trial name
- NCT02581007
- Testing
- Fludarabine, Melphalan, Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Northside Hospital, Inc.
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
Recent studies of conventional chemotherapy for infants with high-risk hematologic malignancies show that the long-term disease-free survival is low.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia
- Trial name
- NCT00145626
- Testing
- Chemotherapy and antibodies, Miltenyi Biotec CliniMACS, Allogeneic stem cell transplantation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR
This research study is for subjects that are receiving a bone marrow transplant. As part of the transplant subjects will receive stem cells from a donor who has agreed to donate stem cells for them.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- TAR (NCT01611298)
- Testing
- Tetanus
- Where
- 2 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Robert Krance
Chronic Myeloproliferative Disorders, Leukemia
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill metastatic cancer cells. Interferon alfa may interfere with the growth of the cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00002504
- Testing
- aldesleukin, recombinant interferon alfa
- Where
- 5 sites in United States
- Sponsor
- Hoag Memorial Hospital Presbyterian
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
The purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-CD33 bispecific antibody (CD33Bi) armed fresh peripheral blood mononuclear cells (CD33Bi FPBMC) for patients with acute…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- AML-MDS 001 (NCT07270978)
- Testing
- CD33 FPBMC
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Virginia
Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
This phase II trial studies the side effect of busulfan, fludarabine phosphate, and post-transplant cyclophosphamide in treating patients with blood cancer undergoing donor stem cell transplant.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Lymphoproliferative Disorder
- Trial name
- NCT02861417
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Neoplasms
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
This trial will evaluate the safety and efficacy of post-transplant Cy and sirolimus following reduced intensity allogeneic SCT.
- Trial name
- NCT01244906
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Northside Hospital, Inc.
Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
The purpose of this study is to reduce the risk of cancer relapse by giving a donor lymphocyte infusion (DLI) to boost the immune system early after a stem cell transplant so that leukemia cells that escaped chemotherapy can be…
- Conditions
- Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
- Trial name
- NCT03939585
- Testing
- Cellular therapy product
- Where
- United States
- Sponsor
- Leland Metheny
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating young…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00030108
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Trial name
- NCT00027924
- Testing
- busulfan, cyclosporine, fludarabine phosphate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
This randomized phase II/III trial studies how well azacitidine works with or without lenalidomide or vorinostat in treating patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.
- Conditions
- Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome
- Trial name
- NCT01522976
- Testing
- Azacitidine, Laboratory Biomarker Analysis, Lenalidomide
- Where
- 294 sites in United States, Canada
- Volunteers
- 282 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
The goal of this clinical research study is to find the highest tolerable dose of AT9283 that can be given to patients who have ALL, AML, CML, high-risk myelodysplastic syndromes, or myelofibrosis with myeloid metaplasia.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00522990
- Testing
- AT9283
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Acute Leukemia, Chronic Myeloproliferative Disease
A Phase I Trial of ZIO-101 in Hematologic Cancers
This study uses a new investigational (not yet approved by the FDA for widespread use) drug called ZIO-101, an organic arsenical.
- Conditions
- Acute Leukemia, Chronic Myeloproliferative Disease, Chronic Lymphoproliferative Disease, Multiple Myeloma
- Trial name
- NCT00592046
- Testing
- ZIO-101 (Darinaparsin)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Alaunos Therapeutics
Breast Cancer, Chronic Myeloproliferative Disorders
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and peripheral stem cell transplantation with biological therapy may kill more cancer…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003408
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cancer Treatment Centers of America
Chronic Myeloid Leukemia
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia
Ponatinib has shown to induce deeper molecular responses compared with imatinib. Therefore, ponatinib treatment could increase the proportion of patients who could discontinue treatment successfully.
- Trial name
- NCT04043676
- Testing
- Ponatinib
- Where
- 9 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Fundación Teófilo Hernando, Spain
Hodgkin's Lymphoma, Lymphoid Leukemia
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Determine the relapse-free, donor lymphocyte infusion (DLI)-free survival in patients receiving the investigational regimen.This is a randomized phase II clinical trial, comparing two different dosing schedules of mycophenolate…
- Conditions
- Hodgkin's Lymphoma, Lymphoid Leukemia, Lymphoma, Leukemia
- Trial name
- NCT02593123
- Testing
- mycophenolate mofetil, Sargramostim, Filgrastim
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Virginia Commonwealth University
Juvenile Myelomonocytic Leukemia, Neurofibromatosis Type 1
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory).
- Trial name
- NCT03190915
- Testing
- Bone Marrow Aspiration and Biopsy, Trametinib
- Where
- 57 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation